Immunotherapy
Datopotamab Deruxtecan + Imfinzi Transform First-Line NSCLC Treatment in TROPION-Lung04 Trial
The TROPION-Lung04 Phase Ib trial has unveiled highly promising results. The trial showcases the potential of datopotamab deruxtecan (Dato-DXd), in ...
Roche’s subcutaneous Tecentriq faces FDA setback due to manufacturing updates
Roche may experience a delay in the FDA decision for its subcutaneous version of the cancer immunotherapy Tecentriq, as it ...
Tecentriq SC: A Swift Leap Forward in Cancer Treatment Receives Green Light
Roche has proudly unveiled that Tecentriq SC (atezolizumab) has received the stamp of approval from the Medicines and Healthcare products ...
Discover the rare yet aggressive uterine sarcoma, its symptoms, causes, and treatments.
A cancer called uterine sarcoma develops in the uterus’s (the womb’s) muscle or other tissues. It is different from endometrial ...
CAR T-Cell Therapy in Hematological Malignancies: A Breakthrough or a Bust?
Hematological malignancies are cancers that affect the blood, bone marrow, and lymph nodes. They include leukemia, lymphoma, and multiple myeloma. ...
Nivolumab and Ipilimumab Together Prolong Survival in Metastatic RCC
Kidney cancer, or renal cell carcinoma (RCC), is one of the most common types of cancer in adults, affecting about ...
How to Counsel Patients on Immunotherapy Discontinuation in RCC
Immunotherapy has revolutionized the treatment of metastatic renal cell carcinoma (RCC), a type of kidney cancer that is often resistant ...
High Cost of New Cancer Drugs and Lack of Awareness Impede Adoption in the US
A new survey conducted by healthcare research firm Sermo revealed that oncologists in the United States perceive pricing as the ...
ASCO 2023: Unlocking the Potential of TGF-β Inhibition
ABSTRACT NUMBER: 6026 Recent studies have underscored the crucial role of the TGF-β signalling pathway in shaping the immune microenvironment ...
